G9830 HCPCS Level II Code: Her-2/neu positive
Medicare Coverage & Payment
- CMS short descriptor: Her-2 pos
- Medicare coverage: Carrier judgment (CMS coverage code C)
- Payment category: Service not separately priced (pricing indicator 00)
- BETOS: Z2 — Undefined codes
- Last CMS action effective: January 1, 2017
Source: CMS HCPCS Level II release. Coverage codes indicate how Medicare treats the code, not whether a specific claim will be paid; payer policy and documentation still govern.
Contextual Map
Every relationship of G9830 in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.
Nearest codes (40)
- G9810 — Patient achieved a pdc of at least 75% for their asthma controller medication[Sibling]— CMS HCPCS Level II code set
- G9811 — Patient did not achieve a pdc of at least 75% for their asthma controller medication[Sibling]— CMS HCPCS Level II code set
- G9812 — Patient died including all deaths occurring during the hospitalization in which the operation was performed, even if after 30 days, and those deaths occurring after discharge from the hospital, but within 30 days of the procedure[Sibling]— CMS HCPCS Level II code set
- G9813 — Patient did not die within 30 days of the procedure or during the index hospitalization[Sibling]— CMS HCPCS Level II code set
- G9814 — Death occurring during the index acute care hospitalization[Sibling]— CMS HCPCS Level II code set
- G9815 — Death did not occur during the index acute care hospitalization[Sibling]— CMS HCPCS Level II code set
- G9816 — Death occurring after discharge from the hospital but within 30 days post procedure[Sibling]— CMS HCPCS Level II code set
- G9817 — Death did not occur after discharge from the hospital within 30 days post procedure[Sibling]— CMS HCPCS Level II code set
- and 32 more
Change history
- January 1, 2017 — Added to the code set [Change history]— CMS release files (code change ledger)
Sources for this page
Codes, titles, notes, index terms and mappings on this page are transcribed from the datasets below. Relationships MedCoder computed and text MedCoder wrote are labelled where they appear.
- Code, descriptors, coverage and pricing attributes Official source data
- CMS HCPCS Alpha-Numeric (ANWEB) release — July 2026 quarterly update Release, file and checksum · Publisher’s page
- Change history and date-of-service validity Official source data
- CMS HCPCS quarterly update files, ingested into the change ledger Release, file and checksum · Publisher’s page
- Comparisons, relationships and the contextual map MedCoder structured relationship
- Computed by MedCoder from the tabular notes and tables above; every derived relationship is marked as derived where it appears
- Summary and FAQ answers MedCoder explanation
- Written by MedCoder to explain the sources above: drafted with AI assistance, checked by a person against the release files, and labelled as MedCoder text where it appears. Not official text.
Labels on this page: Official source data · MedCoder structured relationship · MedCoder explanation. How to read the labels · All data sources and release dates
Change history
- January 1, 2017Added to the code setHer-2/neu positive
Nearest Codes in This Family
Official HCPCS Level II classifications closest to G9830 in its code family, with their registry titles.
- G9825 — Her-2/neu negative or undocumented/unknown
- G9826 — Patient transferred to practice after initiation of chemotherapy
- G9827 — Her2-targeted therapies not administered during the initial course of treatment
- G9828 — Her2-targeted therapies administered during the initial course of treatment
- G9829 — Breast adjuvant chemotherapy administered
- G9831 — Ajcc stage at breast cancer diagnosis = ii or iii
- G9832 — Ajcc stage at breast cancer diagnosis = i (ia or ib) and t-stage at breast cancer diagnosis = t1c
- G9833 — Patient transfer to practice after initiation of chemotherapy
- G9834 — Patient has metastatic disease at diagnosis
- G9835 — Trastuzumab administered within 12 months of diagnosis